OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2– Breast Cancer

Highlights from the PER® CME activity "OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2– Breast Cancer" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; and Seth A. Wander, MD, PhD; discuss real-world insights into tailoring adjuvant therapy regimens in hormone receptor–positive/HER2-negative (HR+/HER2–) early breast cancer (eBC).

Earn CME credit by completing the full accredited activity (available through April 20, 2027):
https://www.gotoper.com/courses/oncobytes-adaptive-learning-pathways-personalizing-treatment-plans-to-optimize-adjuvant-therapy-in-early-stage-hrher2-breast-cancer

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme LLC.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.